Delivery Order SPE2DB20D2104-SPE2DB24FR62W
- Not listed
- This federal contract award is for the delivery of RabAvert rabies vaccine with diluents, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,033.42 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the supply of RabAvert rabies vaccine with diluents. The $2,095.80 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- This federal contract award is for the delivery of RABAVERT rabies vaccine with diluents, awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA). The $3,860.60 firm fixed price delivery order has a completion date of November 1, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026 to provide a comprehensive range of medical commodities,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RabAvert rabies vaccine with diluents. The fixed-price delivery order has a ceiling value of $1,930.30 and an ultimate completion date of April 23, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of RabAvert rabies vaccine with diluents. The award, valued at $2,702.42, is a firm fixed price delivery order contract with a completion date of March 26, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. In addition to this specific award, Amerisourcebergen Drug Corp holds a...
- This federal contract award is for the delivery of RabAvert rabies vaccine with diluents, awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,095.80 and is a firm fixed-price delivery order with an ultimate completion date of April 24, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the delivery of RabAvert rabies vaccine with diluents, awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,702.29 firm-fixed price delivery order was issued by the Defense Logistics Agency (DLA) on September 16, 2022, with a completion date of September 19, 2022. This contract does not have a set-aside designation, indicating full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RabAvert rabies vaccine with diluents. The $36,044.80 firm fixed-price delivery order is a part of a larger $999,999,999 Indefinite Delivery Contract between Amerisourcebergen and the DLA Troop Support Medical division, which serves as the primary vehicle for the company to supply a comprehensive range of pharmaceutical products...
- This federal contract award is for the delivery of RABAVERT RABIES VACCINE WITH DILUENTS to the Defense Logistics Agency (DLA), a defense agency. The $48,309.89 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, on June 25, 2024, with a completion date of June 26, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $6,949.08 firm-fixed-price delivery order is for RabAvert rabies vaccine with diluents. The award is not associated with a set-aside designation. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FR62WDelivery Order
This federal contract award is for the delivery of RabAvert rabies vaccine with diluents, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $14,743.20 firm fixed price delivery order is a part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, generic drugs, vaccines, and medical devices, to support the healthcare needs of the Department of Defense and other federal agencies. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.7k | 12/14/23 |